Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) fell 5.3% on Wednesday . The stock traded as low as $20.19 and last traded at $20.22, with a volume of 90,304 shares traded. The stock had previously closed at $21.35.

Several research firms recently weighed in on BPMC. Cowen and Company restated a “buy” rating on shares of Blueprint Medicines Corp. in a research note on Tuesday, May 10th. Zacks Investment Research cut Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Finally, Raymond James Financial Inc. began coverage on Blueprint Medicines Corp. in a research report on Friday, May 27th. They issued an “outperform” rating and a $23.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $28.50.

The stock’s 50-day moving average is $19.58 and its 200-day moving average is $18.15. The firm’s market cap is $548.79 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.13. The firm earned $6.90 million during the quarter, compared to analyst estimates of $3.24 million. The company’s quarterly revenue was up 961.5% compared to the same quarter last year. Equities analysts anticipate that Blueprint Medicines Corp. will post ($3.10) earnings per share for the current fiscal year.

In other Blueprint Medicines Corp. news, CEO Jeffrey W. Albers sold 17,000 shares of the company’s stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $20.03, for a total value of $340,510.00. Following the completion of the transaction, the chief executive officer now owns 92,486 shares in the company, valued at $1,852,494.58. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.